Protein microarray has solved the long-standing dilemma of reduced protein functionality and erroneous protein conformation prevalent in many protein array methodologies
Sigma-Aldrich announces the launch of Panorama human p53 protein functional microarray.
Developed by Procognia and distributed exclusively by Sigma-Aldrich, the p53 protein microarray is based on a novel and proprietary technology that ensures the protein is correctly folded and confers full functionality.
The p53 protein microarray contains wild type human p53 and 49 variants.
Each p53 variant contains a mutation or single nucleotide polymorphism (SNP) resulting in an amino acid change or a truncation.
Forty-five of the variants are known germ-line mutations associated with cancer.
"The novel technology that Procognia has developed to immobilise functional proteins in a microarray format provides us with a superior platform technology," commented Michael Hadjisavas, global marketing manager of proteomics at Sigma-Aldrich.
"It has solved the long-standing dilemma of reduced protein functionality and erroneous protein conformation prevalent in many protein array methodologies.
"Unlike other protein array technologies, our functional protein array gives researchers the confidence of knowing their data is based on interaction with a fully functional immobilised protein".
Additional protein arrays to be launched in the coming months will contain selected sets of biologically related human proteins including collections of proteins associated with key diseases such as cancer and signal transduction, says Sigm-Aldrich.
